Core Insights - Asensus Surgical, Inc. has received FDA 510(k) clearance for the Senhance® Surgical System to treat adult and pediatric Urology patients, marking a significant milestone for the company in expanding its market presence in the U.S. [1] - The Senhance System is designed to enhance surgical precision and reduce variability through Augmented Intelligence and deep learning capabilities, making it suitable for urological procedures [2][3] - The U.S. healthcare providers conduct over 185,000 urological surgical procedures annually, indicating a substantial market opportunity for the Senhance System [1] Company Overview - Asensus Surgical is recognized as a leader in innovative digital solutions for the operating room, focusing on making surgery more accessible and predictable while achieving superior outcomes [3] - The company is committed to revolutionizing surgery with its intra-operative Augmented Intelligence technology and has a global presence with system placements [3] Market Context - The expanded indication for the Senhance System will allow healthcare providers in the U.S. to leverage its advantages in urological surgery, which has been successfully utilized in other markets for several years [1] - The integration of a full suite of 3mm and 5mm instruments with digital capabilities positions the Senhance System as a significant advancement in minimally invasive surgery for both adult and pediatric patients [2]

Core Insights - Asensus Surgical, Inc. has received FDA 510(k) clearance for the Senhance® Surgical System to treat adult and pediatric Urology patients, marking a significant milestone for the company in expanding its market presence in the U.S. [1][4] - The Senhance System is designed to enhance surgical precision and control through advanced digital capabilities, making it suitable for urological procedures [1][2]. Company Overview - Asensus Surgical is recognized as a leader in innovative digital solutions for the operating room, focusing on making surgery more accessible and predictable while achieving superior outcomes [3]. - The company is committed to revolutionizing surgery with its intra-operative Augmented Intelligence technology, which has been approved for use globally [3]. Market Context - In the U.S., healthcare providers perform over 185,000 urological surgical procedures annually, indicating a substantial market opportunity for the Senhance System [1]. - The expanded indication for the Senhance System is expected to leverage its advantages in the U.S. patient population, where it has already been successfully utilized for urology procedures outside the U.S. [1].

RESEARCH TRIANGLE PARK, N.C., July 16, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and patient, announced that LKH-Universitätsklinikum Graz in Austria has entered into an agreement to lease and utilize a Senhance® Surgical System. LKH-Universitätsklinikum Graz is a renowned healthcare institution known for its expertise in minimally invasive pediatric and adolescent surgery. This hospital will be the 7t ...

Asensus Surgical, Inc. (ASXC) announced an agreement with St. Marianna University School of Medicine Yokohama City Seibu Hospital in Japan on leasing its Senhance Surgical System. The hospital will use the system in its Urology and Gastroenterology/General Surgery department. The Senhance Surgical System can effortlessly integrate human skills with clinical intelligence. Asensus Surgical's latest deal on this system underscores the hospital's dedication to medical innovation.More on the NewsThe Senhance Sur ...

Asensus Surgical Inc. (ASXC) gets into a definitive merger agreement with KARL STORZ Endoscopy-America, Inc., a wholly owned subsidiary of KARL STORZ SE & Co. KG. The merger agreement states that KARL STORZ will acquire all of the outstanding shares of Asensus Surgical for 35 cents per share in cash.The merger is expected to maximize Asensus Surgical’s stockholder value. With this transaction, Asensus will have a greater opportunity to advance in safer, predictable surgery and digital tools for patients and ...

Core Viewpoint - Monteverde & Associates PC is investigating Asensus Surgical, Inc. regarding its proposed merger with KARL STORZ Endoscopy-America, Inc., which involves acquiring each outstanding share of Asensus Surgical stock for $0.35 in cash [1] Company Overview - Monteverde & Associates PC is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report and has a successful track record in recovering money for shareholders [1][2] - The firm operates from the Empire State Building in New York City and specializes in class action securities litigation [2] Merger Details - The merger agreement stipulates that KARL STORZ Endoscopy-America, Inc. and Karl Storz California Inc. will acquire Asensus Surgical shares at a price of $0.35 per share, without interest [1]

Core Viewpoint - Ademi LLP is investigating Asensus Surgical for potential breaches of fiduciary duty and other legal violations related to its transaction with KARL STORZ, where shareholders will receive only $0.35 per share in cash [1] Group 1: Transaction Details - Asensus Surgical shareholders will receive $0.35 per share in cash as part of the transaction [1] - The transaction agreement imposes significant penalties on Asensus Surgical for accepting competing bids, thereby limiting competition [1] - Insiders of Asensus Surgical are set to receive substantial benefits through change of control arrangements [1] Group 2: Investigation Focus - The investigation is centered on the conduct of Asensus Surgical's board of directors and whether they are fulfilling their fiduciary duties to all shareholders [1]

KARL STORZ to acquire Asensus for $0.35 per share in cash Creating a leading surgical robotics division within KARL STORZ RESEARCH TRIANGLE PARK, N.C., June 07, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC) (“Asensus Surgical” or “Asensus”), a global leader of innovative digital solutions for the operating room, today announced that it has entered into a definitive merger agreement (the “Merger Agreement”) with KARL STORZ Endoscopy-America, Inc. ("KARL STORZ"), a wholly owned direct ...

KARL STORZ to acquire Asensus for $0.35 per share in cash Creating a leading surgical robotics division within KARL STORZ RESEARCH TRIANGLE PARK, N.C., June 07, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE:ASXC) ("Asensus Surgical" or "Asensus"), a global leader of innovative digital solutions for the operating room, today announced that it has entered into a definitive merger agreement (the "Merger Agreement") with KARL STORZ Endoscopy-America, Inc. ("KARL STORZ"), a wholly owned direct subsidiary ...